Rafagen Overview

  • Founded
  • 2007

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Rafagen General Information


Developer of next generation gene expression systems designed to solve problems in molecular therapeutics. The company's gene expression systems are developed with genetically engineered CHO cells and also provides services like gene cloning, codon optimization, gene synthesis, cell culture scale up, cell based assays and fow cytometry, enabling physicians to kill cancer cells with the highest possible efficiencies while leaving normal cells unharmed.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Primary Office
  • 9700 Great Seneca Highway
  • Suite 191
  • Rockville, MD 20850
  • United States
+1 (301) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rafagen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 01-Aug-2016 00000 Completed Out of Business
4. Grant 04-Nov-2010 00000 Completed Startup
3. Early Stage VC 16-Dec-2009 00000 Completed Startup
2. Early Stage VC 01-Apr-2009 $237K Completed Startup
1. Accelerator/Incubator 09-Jul-2008 $237K $237K Completed Startup
To view Rafagen’s complete valuation and funding history, request access »

Rafagen Executive Team (3)

Name Title Board Seat Contact Info
Ja Koo Ph.D Co-Founder & Chief Technology Officer
You’re viewing 1 of 3 executive team members. Get the full list »